KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Bionano Genomics (BNGO) Free Cash Flow (2017 - 2025)

Bionano Genomics (BNGO) has disclosed Free Cash Flow for 9 consecutive years, with -$4.1 million as the latest value for Q4 2025.

Quarterly Free Cash Flow rose 36.96% to -$4.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$16.3 million through Dec 2025, up 76.39% year-over-year, with the annual reading at -$16.3 million for FY2025, 76.39% up from the prior year.
Free Cash Flow hit -$4.1 million in Q4 2025 for Bionano Genomics, up from -$5.9 million in the prior quarter.
In the past five years, Free Cash Flow ranged from a high of -$2.8 million in Q1 2025 to a low of -$36.6 million in Q2 2023.
Historically, Free Cash Flow has averaged -$20.6 million across 5 years, with a median of -$23.7 million in 2021.
Biggest five-year swings in Free Cash Flow: plummeted 139.69% in 2022 and later soared 90.18% in 2025.
Year by year, Free Cash Flow stood at -$26.3 million in 2021, then crashed by 37.35% to -$36.1 million in 2022, then rose by 13.95% to -$31.0 million in 2023, then skyrocketed by 79.04% to -$6.5 million in 2024, then soared by 36.96% to -$4.1 million in 2025.
Business Quant data shows Free Cash Flow for BNGO at -$4.1 million in Q4 2025, -$5.9 million in Q3 2025, and -$3.5 million in Q2 2025.